Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes with consideration to new data emerging from SGLT2 inhibitors and GLP-1 Receptor Agonists.
More from this programme
Part 1
Diabetes and Heart Failure Outcomes
| 1 session | |
| Diabetes and Heart Failure Outcomes | Watch now |
Part 2
SGLT2 Inhibitors in Heart Failure
| 1 session | |
| SGLT2 Inhibitors in Heart Failure | Watch now |
Part 3
GLP-1 Receptor Agonists in Heart Failure
Faculty Biographies
Mikhail Kosiborod
Professor of Medicine
Dr Mikhail Kosiborod is a cardiologist based in the United States, where he serves as Senior Vice President, Late-stage Development, CVRM at AstraZeneca and Professor of Medicine at the University of Missouri…
Mark Petrie
Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)
Prof Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK. Prof Petrie started his studies as an undergraduate at Edinburgh University, before training in cardiology in Glasgow. He worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016.
Prof Petrie's research interests focus on diabetes and cardiovascular disease in heart failure, structural intervention and revascularization in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, postmyocardial infarction cardiac remodeling, iron in heart failure, and cardio-oncology. While Prof Petrie has many research interests, he also takes pleasure in mentoring future high-caliber cardiologists and has supervised many outstanding individuals during their PhDs and MDs.